leadf
logo-loader
viewOpen Orphan PLC
(
AIM:ORPHFRA:CRO
)

Open Orphan has 'firmly established its core pharma services offering'

Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). 

She says ORPH has firmly established its core pharma services offering, underpinned
by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. 

ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already
signed with the UK Government for COVID-19 vaccine challenge studies.

Click here to read Proactive analyst Emma Ulker's latest research note on 'Open Orphan: Unlocking the value of non-core assets'

Quick facts: Open Orphan PLC

Follow
AIM:ORPH

Price: 25.5 GBX

Market Cap: £171.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

London's FTSE 100 opens lower despite a strong performance in Asia and...

FTSE 100 opened lower despite a strong performance in Asian markets overnight and US futures pointing up after Labor Day weekend. London’s leading index dropped 16 points to 7,171 in early trading. Hyundai Motor Group will offer the option to power passenger vehicles and commercial vans,...

1 week, 5 days ago

2 min read